Adjuvant immunotherapy in the modern management of resectable melanoma: current status and outlook to 2028
Open Access
Abstract
No abstract availableKeywords
Funding Information
- Danmarks Frie Forskningsfond (2034-00406B)
- Novo Nordisk Fonden (0081557)
- Wellcome Trust (225724/Z/22/Z)
This publication has 25 references indexed in Scilit:
- Systemic Therapy for Melanoma: ASCO Guideline UpdateJournal of Clinical Oncology, 2023
- Common Sense Oncology: outcomes that matterThe Lancet Oncology, 2023
- Survival after introduction of adjuvant treatment in stage III melanoma: a nationwide registry-based studyJNCI: Journal of the National Cancer Institute, 2023
- Evaluating Trials of Adjuvant Therapy: Is There Benefit for People With Resected Renal Cancer?Journal of Clinical Oncology, 2023
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238Clinical Cancer Research, 2023
- Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced MelanomaNew England Journal of Medicine, 2023
- Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survivalCancer Immunology, Immunotherapy, 2022
- Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk MelanomaCancer Discovery, 2022
- Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 TrialJournal of Clinical Oncology, 2020
- Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manualCA: A Cancer Journal for Clinicians, 2017